Evidence map›Paper›PMID 30609963›Full record

ArticleTrends in pharmacological sciences2019

Affordable Preeclampsia Therapeutics.

Elizabeth Lemoine, Ravi Thadhani

Abstract readComment
PubMed Publisher
In one paragraph

Article in Trends in pharmacological sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. The GenusFrontiers in pharmacology · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Elizabeth LemoineHarvard Medical School, Boston, MA, USA; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Ravi ThadhaniHarvard Medical School, Boston, MA, USA; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: ravi.thadhani@csmc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preeclampsia is one of the leading causes of maternal and perinatal morbidity and mortality, particularly in resource-limited settings. Treatment options for this devastating condition remain extremely limited. The successful application of RNAi technology to suppress the pathogenic protein soluble FMS-like tyrosine kinase-1 (sFLT1) in a baboon model of preeclampsia portends the development of effective therapies potentially accessible to areas with the greatest burden of disease.

Indexed as

Pre-EclampsiaFemaleHumansPlacentaPregnancyRNA InterferenceVascular Endothelial Growth Factor Receptor-1FLT1 protein, humanVascular Endothelial Growth Factor Receptor-1hypertensive disorders of pregnancypreeclampsiapreeclampsia therapeuticsRNAisFLT1siRNA

Identifiers

PMID30609963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.